Antibacterial therapy of vulgar acne

Cover Page

Abstract


Purpose: to evaluate the efficacy and safety of minocycline in the therapy of medium-heavy and severe forms of acne vulgaris according to modern ideas about pathogenesis of the disease.

Materials and methods. Long-term multi-purpose observation which included 28 patients with the established diagnosis of acne vulgaris, medium-weight and severe forms is made. Patients received monotherapy by Minoleksin® medicine, depending on severity — 50–100 mg a day. Prior to the research and after the end of treatment inspection of the patient with calculation the rash elements, clinical and biochemical blood analysis, a research of function of sebaceous glands, the laser scanning microscopy, a laser Doppler floumetry, definition of the dermatological index of quality of life, photography (was performed at the consent of the patient). In the course of therapy inspection of the patient and assessment of tolerance of drug was performed.

Results. The evidence of efficiency of minocycline in treatment of vulgar acnes of average and heavy severity is obtained that is confirmed by visual dermatological indicators, non-invasive methods of a research (results of a sebumetriya, the confocal laser scanning microscopy, a Doppler floumetriya), indicators of the dermatological index of quality of life. When studying clinical and laboratory indicators security concerns are not revealed. The undesirable phenomena in the course of the research are not registered.

Conclusion. Minolexin® (minocycline) is highly effective and safe drug for treatment of vulgar acnes of average and heavy severity and it can be recommended for practical application in out-patient practice.

Conflict of interest: the author states that there is no potential conflict of interest requiring disclosure in this article.


E. S. Snarskaya

I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation

Author for correspondence.
Email: snarskaya-dok@mail.ru

Russian Federation Elena S. Snarskaya — Dr. Sci. (Med.), Prof. of the Department of Skin and Venereal Diseases

  1. Do T. T., Zarkhin S., Orringer J. S. Computer-assisted alignment and tracking of acne lesions indicate that most inflammatory lesions arise from comedones and de novo. J Am Acad Dermatol. 2008;58(4):603–608.
  2. Kircik L. H. Revaluating treatment targets in acne vulgaris: adapting to a new understanding of pathophysiology. J Drugs Dermatol. 2014;13(6):s57–60.
  3. Rocha M. A., Costa C. S., Bagatin E. Acne vulgaris: an inflammatory disease even before the onset of clinical lesions. Inflamm Allergy Drug Targets. 2014;13(3):162–167.
  4. Beyot С., Auffret N., Poli F. et al. Propionibacterium acnes: an update on its role in the pathogenesis of acne. JEADV. 2014;3:271–278.
  5. Leeming J., Holland K., Cunliffe W. J. The microbial colonization of inflamed acne vulgaris lesions. Br J Dermatol. 1988;118(2):203–208.
  6. Zaleski-Larsen L. A., Fabi S. G., McGraw T., Taylor M. Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type. Dermatol Surg. 2016 May;42(Suppl 2):139–149.
  7. Gollnick H. P., Graupe K., Zaumseil R. P. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol. 2001;11(6):538–544.
  8. Torok H. M. MD Extended-release Formulation of Minocycline in the Treatment of Moderate-to-severe Acne Vulgaris in Patients over the Age of 12 Years. J Clin Aesthet Dermatol. 2013 Jul;6(7):19–22.
  9. Федеральные клинические рекомендации по ведению больных акне. М., 2015.
  10. Анисимова М. Ю. Акне (acne vulgaris) с позиции доказательной медицины. Вестник репродуктивного здоровья. 2010 Декабрь:14–22.
  11. Острецова М. Н. Современный взгляд на проблему этиопатогенеза и классификации рубцовых проявлений симптомокомплекса постакне. Российский журнал кожных и венерических болезней. 2017;20(3):167–173.

Views

Abstract - 83

PDF (Russian) - 37

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies